

1625/IFW

Docket No.
434-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Ask Puschl, et al.

Confirmation No.

Application No.: 10/551,883

Group Art Unit: 1625

Filing or 371(c) Date: November 29, 2005

Examiner: Celia C. Chang

For: 4-(2Phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors

Date: **October 19, 2006**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Supplemental Information Disclosure Statement by Applicant form (PTO/SB/08a). Copies of the three (3) documents listed on the enclosed PTO/SB/08a form are enclosed herewith.


This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office action on the merits. Accordingly, neither a fee nor Statement under 37 C.F.R. § 1.97(e) is due. However, if a first Office Action has been mailed, authorization is given to charge the fee under 37 C.F.R. § 1.17(p) (\$180) to Deposit Account No. 50-3201.

It is respectfully requested that the above information be considered by the Examiner and that an initialed copy of the accompanying Information Disclosure Statement by Applicant form (PTO/SB/08a) be returned to the undersigned indicating that such information has been considered.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee is deemed necessary in connection with filing this Supplemental Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge this fee to Deposit Account Number 50-3201.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Nicholas J. Sisti", is written over a horizontal line.

Nicholas J. Sisti
Reg. No. 54,453
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
Tel: 201-350-0781
Fax: 201-225-9571

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of	1
----	---

Complete if Known

Application Number	10/551,883
Filing Date	November 29, 2005
First Named Inventor	Ask Puschl
Art Unit	1625
Examiner Name	Chang, Celia C.
Attorney Docket Number	434-US-PCT

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
		EP 0 755 923	04-05-2005	Annoura, et al.		
		WO 2001/49678	07-12-2001	H. Lundbeck A/S		
		WO 2001/49681	07-12-2001	H. Lundbeck A/S		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



DocId: 34444444
434-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ask Puschl, et al.

Group Art Unit: 1625

Application No.: 10/551,883

Examiner: Celia C. Chang

Filing or 371(c) Date: November 29, 2005

For: 4-(2Phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors

Date: October 19, 2006

CERTIFICATE OF MAILING
BY "FIRST CLASS MAIL" (37 C.F.R. § 1.8)

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following correspondence:

Supplemental Information Disclosure Statement (2 pages); Form PTO/SB08/a (1 page); Copies of three (3) references; and Return Postcard

is being deposited on October 19, 2006 with the United States Postal Service as first class mail in an envelope bearing sufficient postage thereon and addressed to:

**Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450.**

Kathleen A. Andree-Cuneo

(Typed Or Printed Name Of Person Mailing Correspondence)

Kathleen A. Andree-Cuneo

(Signature Of Person Mailing Correspondence)